La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Huakang Biomedical Holdings Bilan de santé

Santé financière contrôle des critères 5/6

Huakang Biomedical Holdings possède un total de capitaux propres de CN¥56.5M et une dette totale de CN¥2.9M, ce qui porte son ratio d'endettement à 5.1%. Son actif total et son passif total sont CN¥66.8M et de CN¥10.3M.

Informations clés

5.1%

Ratio d'endettement

CN¥2.88m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	CN¥36.66m
Fonds propres	CN¥56.50m
Total du passif	CN¥10.29m
Total des actifs	CN¥66.79m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Jun 11

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 8622 ( CN¥56.3M ) dépassent ses passifs à court terme ( CN¥9.7M ).

Passif à long terme: Les actifs à court terme de 8622 ( CN¥56.3M ) dépassent ses passifs à long terme ( CN¥611.0K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 8622 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 8622 est passé de 0% à 5.1% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 8622 dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: 8622 dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de croître à un taux historique de 23.8 % chaque année

Huakang Biomedical Holdings Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.004 loss in 1H 2023)

Huakang Biomedical Holdings Company Limited to Report First Half, 2024 Results on Aug 16, 2024

New minor risk - Share price stability

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 18, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.007 million.

Full year 2023 earnings released: CN¥0.014 loss per share (vs CN¥0.008 loss in FY 2022)

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 3.224 million.

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 5.952 million.

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

New minor risk - Shareholder dilution

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

Chairman of the Board recently sold HK$815k worth of stock

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 8.61 million.

Insufficient new directors

Vice Chairman recently sold HK$2.9m worth of stock

Third quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 profit in 3Q 2022)

Huakang Biomedical Holdings Company Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 loss in 2Q 2022)

Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee

Huakang Biomedical Holdings Company Limited to Report First Half, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 1Q 2022)

Full year 2022 earnings released: CN¥0.008 loss per share (vs CN¥0.011 loss in FY 2021)

Vice Chairman recently sold HK$101k worth of stock

Less than half of directors are independent

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.60496 million.

Second quarter 2022 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 2Q 2021)

Huakang Biomedical Holdings Company Limited to Report First Half, 2022 Results on Aug 08, 2022

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 17, 2022

First quarter 2022 earnings released: CN¥0.002 loss per share (vs CN¥0.003 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.011 loss per share (vs CN¥0.029 loss in FY 2020)

Huakang Biomedical Holdings Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2021

Third quarter 2021 earnings released: CN¥0.001 loss per share (vs CN¥0.001 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.002 loss per share (vs CN¥0.008 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.003 loss per share (vs CN¥0.007 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.029 loss per share (vs CN¥0.001 loss in FY 2019)

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2020 Results on Mar 24, 2021

Huakang Biomedical Holdings Company Limited Announces Management Changes

Third quarter 2020 earnings released: CN¥0.001 loss per share

Huakang Biomedical Holdings Company Limited to Report Q3, 2020 Results on Nov 10, 2020

Earnings released

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines